IL31 and Alzheimer disease: In the last decade, drugs that target the IL-31 pathway, such as lokivetmab (caninized monoclonal antibody against canine IL-31) [12] and nemolizumab (humanized monoclonal antibody against human IL-31RA) [13], have significantly reduced itch and cutaneous inflammation scores in canine and human AD patients, respectively.